Search

Your search keyword '"Piccioli M"' showing total 221 results
Start Over Author "Piccioli M" Language english
221 results on '"Piccioli M"'

5. Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, RealWorld Study

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Cerulli Irelli, E., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Di Gennaro, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Gangitano, M., La Neve, A., Mecarelli, O., Montalenti, E., Morano, A., Piazza, F., Pizzanelli, C., Pulitano, P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Di Giacomo, R., Di Liberto, A., Domina, E., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fisco, G., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giallonardo, A. T., Giorgi, F. S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Milano, C., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quarato, P. P., Quintas, R., Renna, R., Rizzo, G. R., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Vaudano, A. E., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., Zummo, L., Lattanzi, Simona, Canafoglia, Laura, Canevini, Maria Paola, Casciato, Sara, Cerulli Irelli, Emanuele, Chiesa, Valentina, Dainese, Filippo, De Maria, Giovanni, Didato, Giuseppe, Di Gennaro, Giancarlo, Falcicchio, Giovanni, Fanella, Martina, Ferlazzo, Edoardo, Gangitano, Massimo, La Neve, Angela, Mecarelli, Oriano, Montalenti, Elisa, Morano, Alessandra, Piazza, Federico, Pizzanelli, Chiara, Pulitano, Patrizia, Ranzato, Federica, Rosati, Eleonora, Tassi, Laura, and Di Bonaventura, Carlo

Subjects
Antiseizure medication, Focal seizures, Brivaracetam, Epilepsy, Neurology, Settore MED/26 - Neurologia, Neurology (clinical), Settore MED/26, Settore MED/39 - Neuropsichiatria Infantile
Abstract

Introduction: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events (AEs) and the incidence of AEs. Data were compared for patients treated with add-on BRV after 1-2 (early add-on) and ≥ 3 (late add-on) prior antiseizure medications. Results: A total of 1029 patients with focal epilepsy were included in the study, of whom 176 (17.1%) received BRV as early add-on treatment. The median daily dose of BRV at 12months was 125 (100-200) mg in the early add-on group and 200 (100-200) in the late add-on group (p

Published
2022

8. structural and functional characterization of FhuF, a ferric siderophore reductase from E. coli

Author

Trindade, I B, Hernandez, G, Lebègue, E, Barrière, F, Cordeiro, T, Piccioli, M, Louro, R O, Instituto de Tecnologia Química e Biológica António Xavier (ITQB), and Molecular, Structural and Cellular Microbiology (MOSTMICRO)

Abstract

Iron is a fundamental element for virtually all forms of life. Despite its abundance, its bioavailability is limited, and thus, microbes developed siderophores, small molecules, which are synthesized inside the cell and then released outside for iron scavenging. Once inside the cell, iron removal does not occur spontaneously, instead this process is mediated by siderophore-interacting proteins (SIP) and/or by ferric-siderophore reductases (FSR). In the past two decades, representatives of the SIP subfamily have been structurally and biochemically characterized; however, the same was not achieved for the FSR subfamily. Here, we initiate the structural and functional characterization of FhuF, the first and only FSR ever isolated. FhuF is a globular monomeric protein mainly composed by α-helices sheltering internal cavities in a fold resembling the "palm" domain found in siderophore biosynthetic enzymes. Paramagnetic NMR spectroscopy revealed that the core of the cluster has electronic properties in line with those of previously characterized 2Fe-2S ferredoxins and differences appear to be confined to the coordination of Fe(III) in the reduced protein. In particular, the two cysteines coordinating this iron appear to have substantially different bond strengths. In similarity with the proteins from the SIP subfamily, FhuF binds both the iron-loaded and the apo forms of ferrichrome in the micromolar range and cyclic voltammetry reveals the presence of redox-Bohr effect, which broadens the range of ferric-siderophore substrates that can be thermodynamically accessible for reduction. This study suggests that despite the structural differences between FSR and SIP proteins, mechanistic similarities exist between the two classes of proteins. publishersversion epub_ahead_of_print

Published
2021

9. Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST) (CNS Drugs, (2021), 35, 12, (1289-1301), 10.1007/s40263-021-00856-3)

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Irelli, E. C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Gennaro, G., Di Giacomo, R., Di Liberto, A., Domina, E., Donato, F., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Morano, A., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quintas, R., Renna, R., Rossi, J., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., and Zummo, L.

Published
2021

10. Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST) (CNS Drugs, (2021), 10.1007/s40263-021-00856-3)

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Irelli, E. C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Gennaro, G., Di Giacomo, R., Di Liberto, A., Domina, E., Donato, F., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Morano, A., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quintas, R., Renna, R., Rossi, J., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., and Zummo, L.

Published
2021

11. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Irelli, E. C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Di Gennaro, G., Di Giacomo, R., Di Liberto, A., Domina, E., Donato, F., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Morano, A., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quintas, R., Renna, R., Rossi, J., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., Zummo, L., Lattanzi S., Canafoglia L., Canevini M.P., Casciato S., Chiesa V., Dainese F., De Maria G., Didato G., Falcicchio G., Fanella M., Ferlazzo E., Fisco G., Gangitano M., Giallonardo A.T., Giorgi F.S., La Neve A., Mecarelli O., Montalenti E., Piazza F., Pulitano P., Quarato P.P., Ranzato F., Rosati E., Tassi L., and Di Bonaventura C.

Subjects
medicine.medical_specialty, business.industry, Context (language use), Brivaracetam, medicine.disease, Discontinuation, law.invention, Psychiatry and Mental health, Epilepsy, Randomized controlled trial, Tolerability, focal epilepsy, add-on therapy, seizure, law, Concomitant, Internal medicine, Medicine, Pharmacology (medical), Neurology (clinical), Levetiracetam, Original Research Article, business, medicine.drug
Abstract

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure‐freedom, seizure response (≥50% reduction in baseline seizure frequency), and treatment discontinuation. The incidence of adverse events (AEs) was also considered. Analyses by levetiracetam (LEV) status and concomitant use of strong enzyme-inducing antiseizure medications (EiASMs) and sodium channel blockers (SCBs) were performed. Results: A total of 1029 patients with a median age of 45years (33–56) was included. At 12 months, 169 (16.4%) patients were seizure-free and 383 (37.2%) were seizure responders. The rate of seizure freedom was 22.3% in LEV-naive patients, 7.1% in patients with prior LEV use and discontinuation due to insufficient efficacy, and 31.2% in patients with prior LEV use and discontinuation due to AEs (p&nbsp

Published
2021

13. Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. (Original Article)

Author

Pileri, S.A., Sabattini, E., Rosito, P., Zinzani, P.L., Ascani, S., Fraternali-Orcioni, G., Gamberi, B., Piccioli, M., Vivenza, D., Falini, B., and Gaidano, G.

Subjects
Lymphomas -- Development and progression, Testicular cancer -- Development and progression, Health, Development and progression
Abstract

Background/Aims: Paediatric primary follicular lymphoma of the testis (PPFLT) is exceptional: the few reported cases seem to lack BCL-2 gene rearrangement and/or protein expression. The aim of this study was [...]

Published
2002

20. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas

Author

Falini B, Agostinelli C, Bigerna B, Pucciarini A, Pacini R, Tabarrini A, Falcinelli F, Piccioli M, Paulli M, Gambacorta M, Tiacci E, Ascani S, Martelli MP, Favera RD, Stein H, Pileri SA, PONZONI , MAURILIO, Falini B., Agostinelli C., Bigerna B., Pucciarini A., Pacini R., Tabarrini A., Falcinelli F., Piccioli M., Paulli M., Gambacorta M., Ponzoni M., Tiacci E., Ascani S., Martelli M.P., Favera RD., Stein H., Pileri S.A., Falini, B, Agostinelli, C, Bigerna, B, Pucciarini, A, Pacini, R, Tabarrini, A, Falcinelli, F, Piccioli, M, Paulli, M, Gambacorta, M, Ponzoni, Maurilio, Tiacci, E, Ascani, S, Martelli, Mp, Favera, Rd, Stein, H, and Pileri, Sa

Subjects
B-Lymphocytes, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Receptors, Fc, IRTA1, Translocation, Genetic, immunohistochemistry, marginal zone lymphomas, monoclonal antibodies, Biomarkers, Tumor, Humans, Lymph Nodes, immunohistochemistry, IRTA1, marginal zone lymphomas, monoclonal antibodies, In Situ Hybridization, Fluorescence, Spleen
Abstract

Aims: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. Methods and results: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1(+) perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. Conclusions: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms

Published
2012

21. BCL10 expression in peripheral T-Cell lymphoma not otherwise specified

Author

ROSSI, MAURA, AGOSTINELLI, CLAUDIO, GAZZOLA, ANNA, SAPIENZA, MARIA ROSARIA, LAGINESTRA, MARIA ANTONELLA, SAGRAMOSO SACCHETTI, CARLO ALBERTO, SABATTINI, ELENA, BACCI, FRANCESCO, RIGHI, SIMONA, PILERI, STEFANO, Mannu C., Artioli P., Chili L., Sandri F., Piccioli M., Da Pozzo G., Rossi M., Agostinelli C., Gazzola A., Mannu C., Sapienza M.R., Laginestra M.A., Sagramoso C., Sabattini E., Bacci F., Artioli P., Chili L., Sandri F., Piccioli M., Da Pozzo G., Righi S., and Pileri S.A.

Subjects
PTCL NOS, BCL10
Published
2010

22. Use of IGK gene rearrangement analysis for clonality assesment of lymphoid malignancies. A single center experience

Author

Mannu C., Artioli P., Chili L., Da Pozzo G., Piccioli M., Sandri F., SAGRAMOSO SACCHETTI, CARLO ALBERTO, GAZZOLA, ANNA, ROSSI, MAURA, SAPIENZA, MARIA ROSARIA, LAGINESTRA, MARIA ANTONELLA, BACCI, FRANCESCO, SABATTINI, ELENA, AGOSTINELLI, CLAUDIO, RIGHI, SIMONA, PILERI, STEFANO, PICCALUGA, PIER PAOLO, Mannu C., Sagramoso C., Gazzola A., Rossi M., Sapienza M.R., La ginestra A., Bacci F., Sabattini E., Agostinelli C., Artioli P., Chili L., Da Pozzo G., Piccioli M., Righi S., Sandri F., Pileri S.A., and Piccaluga P.P.

Subjects
IGK gene rearrangement, lymphoid malignancie
Published
2010

23. Tissue micro-array in haematopathology:present usage and potential

Author

PILERI, STEFANO, AGOSTINELLI, CLAUDIO, CAMPIDELLI, CRISTINA, RIGHI, SIMONA, BACCI, FRANCESCO, SABATTINI, ELENA, ZINZANI, PIER LUIGI, PICCALUGA, PIER PAOLO, Piccioli M., Pileri S., Agostinelli C., Campidelli C., Righi S., Piccioli M., Bacci F., Sabattini E., Zinzani P.L., and Piccaluga P.P.

Subjects
in haematopathology, Tissue micro-array
Published
2006

24. GENOMIC SIGNATURE OF LEUKEMIC EVOLUTION IN HODGKIN LYMPHOMA

Author

Brusa G., Zuffa E., REMONDINI, DANIEL, Venturini L., Mancini M., Serra M., Hattinger C, Piccioli M., ZINZANI, PIER LUIGI, CAMMELLI, SILVIA, Santucci M. A., BARBIERI, ENZA, CONSORZIO INTERUNIVERSITARIO BIOTECNOLOGIE, Brusa G., Zuffa E., Remondini D., Venturini L., Mancini M., Serra M., Hattinger C, Piccioli M., Zinzani P.L., Cammelli S., Barbieri E., and Santucci M.A.

Abstract

Hodgkin’s lymphoma (HL) is a heterogeneous lymphoid malignancy curable in more than 80% of cases. Its morbility and mortality are mostly contingent upon chemo- and radio-therapy side effects including cardiovascular or pulmonary diseases, infections and second malignancies. Indeed, the high incidence of secondary cancers and leukemias in potentially cured LH patients supports that genomic instability and defective DNA repair system have a crucial role in secondary cancerogenesis/leukemogenesis processes as they let the emergence of genomic aberrations and clonal cell evolution towards a transformed phenotype. The aim of our study was to define the genomic profile associated with HL evolution towards secondary leukemia. To the purpose, formalin-fixed/paraffin-embedded biopsies from 4 LH patients who developed a secondary acute myeloid leukemia (AML) were analyzed by mean of array-based comparative genomic hybridization (aCGH). This method allows the identification of changes in DNA sequence copy number (amplifications or deletions) at high resolution. The microarrays used in our study contain 287 genomic targets involved in most human cancers, including oncogenes, tumor-suppressor genes and DNA sequences localized within chromosomal regions most frequently rearranged. DNAs from lymphonode biopsies of LH patient who developed AML were compared with pooled DNAs from reactive and LH lymphonodes (comparable for histotype and follow-up) from cured patients. CGH profiles of single LH patients were extensively altered. However, they shared a common pattern of structural genomic alterations. Bioinformatic analysis of CGH results performed with dedicated softwares let distinguish statistatically significant (ratio >1,2) amplifications relative to 3 DNA sequences (AFM137XA11, FGFR1, PPABP) and statistatically significant (ratio< 0,83) deletions in 4 (AFM217YD10, FGR(SRC2), GATA3, TOP1, WT1). CGH data relative to the above mentioned sequences were further validated by FISH and immunohistochemistry. In spite of the low number of LH patients our results suggest that the evolution to AML in LH patients may be genetically determined. The role of single genes in leukemic transformation requires further investigation.

Published
2005

26. Toward Structural Dynamics: Protein Motions Viewed by Chemical Shift Modulations and Direct Detection of C ' N Multiple-Quantum Relaxation

Author

Mori, M., Kateb, F., Bodenhausen, G., Piccioli, M., Abergel, Daniel, Université Pierre et Marie Curie - Paris 6 (UPMC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL), Ecole Polytechnique Fédérale de Lausanne (EPFL), École normale supérieure - Paris (ENS-PSL), and Perron, Nicolas

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry
Published
2010

31. Migraine or Epilepsy?

Author

Piccioli, M., Tisei, P., Latella, M. A., Tasillo, M., Ferraldeschi, M., Parisi, Pasquale, Orzi, Francesco, Buttinelli, Carla, and Kasteleijn Nolst Trenité, D. G. A.

Published
2006

33. A genome-wide linkage scan for photoparoxysmal response

Author

Pinto, D, Westland, B, DE HAAN GJ, Parra, J, KASTELEIJN NOIST TRENITE DG, Rudolf, G, Neubauer, B, Stephani, U, DA SILVA AM, Pederson, B, Parain, D, Stroink, H, Lagae, L, Piccioli, M, Brinciotti, Mario, Friis, Ml, Bonnani, P, Covanis, T, Lindhout, D, and Koeleman, Bpc

Published
2003

34. Pathologist's point of view (I): indolent lymphomas

Author

Pileri, S. A., Ascani, Stefano, Sabattini, E., Fraternali Orcioni, G., Poggi, S., Piccioli, M., Piccaluga, P. P., Gamberi, B., Zinzani, P. L., Leoncini, L., and Falini, B.

Subjects
follicular lymphoma, immunophenotyping, nonhodgkin lymphoma, practice guideline, B cell lymphoma, chronic lymphatic leukemia, disease classification, hairy cell leukemia, histopathology, lymphocytoma, lymphoma, mucosa associated lymphoid tissue lymphoma
Published
2000

43. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients

Author

Maria Christina Cox, Cristina Campidelli, Alessandro Pileri, A Gentile, Milena Piccioli, P Rinaldi, Domenico Novero, Stefano Pileri, D Vincelli, Pier Paolo Piccaluga, Silvia Asioli, Brunangelo Falini, Claudio Agostinelli, Vito Franco, Stefano Ascani, Pier Luigi Zinzani, Francesco Bacci, Michele Baccarani, R Gasbarra, M Bisceglia, Maurilio Ponzoni, Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, Piccaluga PP, Agostinelli C, Asioli S, Novero D, Bisceglia M, Ponzoni M, Gentile A, Rinaldi P, Franco V, Vincelli D, Pileri A Jr, Gasbarra R, Falini B, Zinzani PL, Baccarani M., Pileri, Sa, Ascani, S, Cox, Mc, Campidelli, C, Bacci, F, Piccioli, M, Piccaluga, Pp, Agostinelli, C, Asioli, S, Novero, D, Bisceglia, M, Ponzoni, Maurilio, Gentile, A, Rinaldi, P, Franco, V, Vincelli, D, Pileri, A, Gasbarra, R, Falini, B, Zinzani, Pl, Baccarani, M., PILERI SA, ASCANI S, COX MC, CAMPIDELLI C, BACCI F, PICCIOLI M, PICCALUGA, PP, AGOSTINELLI C, ASIOLI S, NOVERO D, BISCEGLIA M, PONZONI M, GENTILE A, RINALDI P, FRANCO V, VINCELLI D, JR AP, GASBARRA R, FALINI B, ZINZANI PL, and BACCARANI M

Subjects
Adult, Genetic Markers, Male, Cancer Research, Pathology, medicine.medical_specialty, Adolescent, Lymphoma, CD34, Biology, Trisomy 8, Translocation, Genetic, cytogenetics, myeloid sarcoma, chloroma, FISH, immunohistochemistry, prognosis, Antigens, CD, medicine, Myeloid sarcoma, Humans, In Situ Hybridization, Fluorescence, Aged, Aged, 80 and over, Chromosome Aberrations, medicine.diagnostic_test, Cytogenetics, Sarcoma, Hematology, Middle Aged, medicine.disease, Transplantation, Leukemia, Phenotype, Oncology, Leukemia, Myeloid, Female, alpha interferonCD30 antigenCD34 antigen, Fluorescence in situ hybridization
Abstract

Myeloid sarcoma ( MS) is a rare neoplasm whose knowledge is largely based on case reports and/or technically dated contributions. Ninety-two MSs in adulthood with clinical data available were evaluated both morphologically and immunohistochemically. Seventy-four cases were also studied by fluorescent in situ hybridization on tissue sections and/or conventional karyotyping on bone marrow or peripheral blood. Histologically, 50% of the tumors were of the blastic type, 43.5% either monoblastic or myelomonocytic and 6.5% corresponded to different histotypes. CD68/KP1 was the most commonly expressed marker (100%), followed by myeloperoxidase (83.6%), CD117 (80.4%), CD99 (54.3%), CD68/PG-M1 (51%), CD34 (43.4%), terminal-deoxy-nucleotidyl-transferase (31.5%), CD56 (13%), CD61/linker for activation of T cells (2.2%), CD30 ( 2.2%) and CD4 (1.1%). Foci of plasmacytoid monocyte differentiation were observed in intestinal cases carrying inv16. Chromosomal aberrations were detected in about 54% of cases: monosomy 7(10.8%), trisomy 8(10.4%) and mixed lineage leukemia-splitting (8.5%) were the commonest abnormalities, whereas t(8; 21) was rare ( 2.2%). The behavior was dramatic irrespective of presentation, age, sex, phenotype and cytogenetics. Most if not all, long survivors received bone-marrow transplantation. The present report expands the spectrum of our knowledge showing that MS has frequent monoblastic/myelomonocytic differentiation, displays distinctive phenotypic profile, carries chromosomal aberrations other than t( 8; 21), and requires supra-maximal therapy.

Published
2007

46. Management of epilepsy in brain tumors

Author

Roberto De Simone, Lucina Carla Vivalda, Alessia Zarabla, Stefano Quadri, Giuliano Avanzini, Gabriella Colicchio, Paolo Tisei, F. Paladin, Umberto Aguglia, Cinzia Costa, Roberto Michelucci, Paolo Vitali, Antonietta Coppola, Giuseppe Capovilla, Ettore Beghi, Andrea Maialetti, Giada Pauletto, Marica Eoli, Gaetano Zaccara, Ornella Daniele, Riccardo Terenzi, F Dainese, Angela La Neve, Paola Banfi, Federica Ranzato, Flavio Villani, Carla Buttinelli, Marta Melis, Rosario Rossi, Marta Piccioli, Anna Teresa Giallonardo, Sara Gasparini, Marina Casazza, Oriano Mecarelli, Marta Maschio, Andrea Salmaggi, Maschio, M., Aguglia, U., Avanzini, G., Banfi, P., Buttinelli, C., Capovilla, G., Casazza, M. M. L., Colicchio, G., Coppola, A., Costa, C., Dainese, F., Daniele, O., De Simone, R., Eoli, M., Gasparini, S., Giallonardo, A. T., La Neve, A., Maialetti, A., Mecarelli, O., Melis, M., Michelucci, R., Paladin, F., Pauletto, G., Piccioli, M., Quadri, S., Ranzato, F., Rossi, R., Salmaggi, A., Terenzi, R., Tisei, P., Villani, F., Vitali, P., Vivalda, L. C., Zaccara, G., Zarabla, A., and Beghi, E.

Subjects
Topiramate, Quality of life, medicine.medical_specialty, Neurology, Interaction, Antiepileptic drugs, Brain tumor, Dermatology, Side effect, Lamotrigine, Brain tumors, Brain Neoplasm, 03 medical and health sciences, Epilepsy, 0302 clinical medicine, medicine, Side effects, Brain Neoplasms, Humans, 030212 general & internal medicine, Intensive care medicine, Valproic Acid, business.industry, General Medicine, medicine.disease, Psychiatry and Mental health, Neurology (clinical), Neurosurgery, Levetiracetam, business, 030217 neurology & neurosurgery, Antiepileptic drug, medicine.drug
Abstract

Epilepsy in brain tumors (BTE) may require medical attention for a variety of unique concerns: epileptic seizures, possible serious adverse effects of antineoplastic and antiepileptic drugs (AEDs), physical disability, and/or neurocognitive disturbances correlated to tumor site. Guidelines for the management of tumor-related epilepsies are lacking. Treatment is not standardized, and overall management might differ according to different specialists. The aim of this document was to provide directives on the procedures to be adopted for a correct diagnostic-therapeutic path of the patient with BTE, evaluating indications, risks, and benefits. A board comprising neurologists, epileptologists, neurophysiologists, neuroradiologists, neurosurgeons, neuro-oncologists, neuropsychologists, and patients' representatives was formed. The board converted diagnostic and therapeutic problems into seventeen questions. A literature search was performed in September-October 2017, and a total of 7827 unique records were retrieved, of which 148 constituted the core literature. There is no evidence that histological type or localization of the brain tumor affects the response to an AED. The board recommended to avoid enzyme-inducing antiepileptic drugs because of their interference with antitumoral drugs and consider as first-choice newer generation drugs (among them, levetiracetam, lamotrigine, and topiramate). Valproic acid should also be considered. Both short-term and long-term prophylaxes are not recommended in primary and metastatic brain tumors. Management of seizures in patients with BTE should be multidisciplinary. The panel evidenced conflicting or lacking data regarding the role of EEG, the choice of therapeutic strategy, and timing to withdraw AEDs and recommended high-quality long-term studies to standardize BTE care.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results